Maxwell Skor
Stock Analyst at Morgan Stanley
(4.54)
# 1,028
Out of 5,010 analysts
248
Total ratings
57.8%
Success rate
17.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Rated: Buy | $273 | $230.05 | +18.67% | 32 | Sep 28, 2026 | |
| PHVS Pharvaris | Rated: Buy | $62 | $31.91 | +94.30% | 94 | Sep 28, 2026 | |
| INSM Insmed | Reiterated: Buy | $218 | $117.67 | +85.26% | 30 | Sep 25, 2026 | |
| RARE Ultragenyx Pharmaceutical | Rated: Hold | $18 → $20 | $14.41 | +38.79% | 15 | Sep 21, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Hold | $60 | $54.09 | +10.93% | 3 | Aug 28, 2026 | |
| ADAG Adagene | Reiterated: Hold | n/a | $3.20 | - | 7 | Aug 17, 2026 | |
| BCYC Bicycle Therapeutics | Reiterated: Hold | n/a | $3.71 | - | 9 | Aug 17, 2026 | |
| MNPR Monopar Therapeutics | Rated: Buy | $115 → $130 | $83.72 | +55.28% | 4 | Aug 17, 2026 | |
| SANA Sana Biotechnology | Rated: Buy | $12 | $2.93 | +309.56% | 4 | Aug 17, 2026 | |
| TCRX TScan Therapeutics | Reiterated: Hold | n/a | $0.34 | - | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $7.75 | +67.74% | 1 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $6 → $7 | $5.22 | +34.23% | 11 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $103 | $66.16 | +55.68% | 21 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9.5 → $3.55 | $0.95 | n/a | 10 | Nov 20, 2024 |
Ascendis Pharma
Sep 28, 2026
Rated: Buy
Price Target: $273
Current: $230.05
Upside: +18.67%
Pharvaris
Sep 28, 2026
Rated: Buy
Price Target: $62
Current: $31.91
Upside: +94.30%
Insmed
Sep 25, 2026
Reiterated: Buy
Price Target: $218
Current: $117.67
Upside: +85.26%
Ultragenyx Pharmaceutical
Sep 21, 2026
Rated: Hold
Price Target: $18 → $20
Current: $14.41
Upside: +38.79%
CRISPR Therapeutics AG
Aug 28, 2026
Reiterated: Hold
Price Target: $60
Current: $54.09
Upside: +10.93%
Adagene
Aug 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.20
Upside: -
Bicycle Therapeutics
Aug 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.71
Upside: -
Monopar Therapeutics
Aug 17, 2026
Rated: Buy
Price Target: $115 → $130
Current: $83.72
Upside: +55.28%
Sana Biotechnology
Aug 17, 2026
Rated: Buy
Price Target: $12
Current: $2.93
Upside: +309.56%
TScan Therapeutics
Aug 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.34
Upside: -
Aug 13, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $7.75
Upside: +67.74%
Aug 13, 2026
Rated: Hold
Price Target: $6 → $7
Current: $5.22
Upside: +34.23%
Jul 23, 2026
Rated: Buy
Price Target: $103
Current: $66.16
Upside: +55.68%
Nov 20, 2024
Reiterated: Buy
Price Target: $9.5 → $3.55
Current: $0.95
Upside: n/a